Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

by @JTC_PALIdev | May 11, 2023 | Press Releases

Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Company expects enrollment to be completed in Q3 2023 Carlsbad, CA, May 11, 2023 — Palisade Bio, Inc....

Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148

by @JTC_PALIdev | Apr 6, 2023 | Press Releases

Carlsbad, CA, April 06, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the Canadian Intellectual Property...

Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148

by @JTC_PALIdev | Apr 5, 2023 | Press Releases

Enrollment triggers milestone payment Carlsbad, CA and Shanghai, China, April 05, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic...

Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

by @JTC_PALIdev | Apr 3, 2023 | Press Releases

Carlsbad, CA, April 03, 2023 — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional...

Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update

by @JTC_PALIdev | Mar 23, 2023 | Press Releases

Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with sufficient cash expected to fund operations into mid-2024 Carlsbad, CA, March 23, 2023 — Palisade Bio, Inc. (Nasdaq: PALI)...